sanofi-aventis

1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 535 432
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com

Summary of Product Characteristics last updated on the eMC: 26/03/2009
SPC Ubretid

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 26/03/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 8 - MARKETING AUTHORISATION NUMBER(S)
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Feb-2009
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 8 - marketing authorisation number changed to PL 04425/0617

Section 9 - date changed to February 2009

Section 10 - date changed to Feburary 2009
Updated on 18/09/2007 and displayed until 26/03/2009
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   06/2007
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 7 (Marketing Authorisation Holder): Change to MA Holder's details
Updated on 23/08/2001 and displayed until 18/09/2007
Reasons for adding or updating:
  • Transferred from eMC version 1
Updated on 10/10/2000 and displayed until 23/08/2001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
   distigmine bromide